Profile picture

Doctor Peter Noseworthy

Mayo Clinic, Rochester (United States of America)
Follow
Biography
Peter Noseworthy, MD is a Professor of Medicine and a Cardiac Electrophysiologist specializing in catheter ablation of cardiac arrhythmias. He completed his Medicine, Cardiology, Chief residency and electrophysiology training at Massachusetts General Hospital and joined the Mayo Clinic faculty in 2013. Dr. Noseworthy maintains a federally funded research program centered on improving the care of patients with cardiac arrhythmias. He has a concurrent role in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery where he works leading several prospective pragmatic RCTs and is leading various analyses of national datasets. He serves as the director of the Mayo Clinic Heart Rhythm and Physiologic Monitoring Laboratory where he leads a multidisciplinary team working to develop novel ECG software-based analysis tools.
Logo ESC

Contributor content

Digital health is the new paradigm - in practice: learn from the masters
Presentation
Digital health is the new paradigm - in practice: learn from the masters
Machine learning in AF detection - the problem/the issue: how can ML be of use in predicting incidental atrial fibrillation
Presentation
Machine learning in AF detection - the problem/the issue: how can ML be of use in predicting incidental atrial fibrillation
Future directions: artificial intelligence for early detection of AF.
Presentation
Future directions: artificial intelligence for early detection of AF.
The effect of shared decision-making for stroke prevention on treatment adherence and safety outcomes in patients with atrial fibrillation: a randomized clinical trial
Presentation
The effect of shared decision-making for stroke prevention on treatment adherence and safety outcomes in patients with atrial fibrillation: a randomized clinical trial
Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants
Presentation
Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants
Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease
Presentation
Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease
Utilization and effectiveness of alirocumab and evolocumab in improving lipid profile in routine clinical practice
Presentation
Utilization and effectiveness of alirocumab and evolocumab in improving lipid profile in routine clinical practice
The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation
Presentation
The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation

ESC 365 is supported by